News J&J takes $2.58bn option to buy in vivo CAR-T firm Sail Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.
Market Access Policy in Focus: What’s new with CMS drug price negotiation,... Hogan Lovells partner Alice Valder Curran returned to elucidate some of the finer points of the latest communication from CMS.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.